# Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

> **NCT01571232** · PHASE2 · COMPLETED · sponsor: **Retina Macula Institute** · enrollment: 20 (actual)

## Conditions studied

- Diabetic Macular Edema
- Non-proliferative Diabetic Retinopathy
- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** dexamethasone intravitreal implant
- **DRUG:** intravitreal bevacizumab

## Key facts

- **NCT ID:** NCT01571232
- **Lead sponsor:** Retina Macula Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-02
- **Final completion:** 2015-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01571232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01571232, "Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01571232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*